We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes.
- Authors
Gerstein, H C; Mohan, V; Avezum, A; Bergenstal, R M; Chiasson, J-L; Garrido, M; MacKinnon, I; Rao, P V; Zinman, B; Jung, H; Joldersma, L; Bosch, J; Yusuf, S; DREAM On (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Ongoing Follow-up) Investigators
- Abstract
The Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) trial reported that 3 years of therapy with rosiglitazone reduced the primary outcome of diabetes or death by 60%. Here we investigated whether an effect on diabetes prevention persists more than 1.5 years after therapy has been discontinued.
- Publication
Diabetologia, 2011, Vol 54, Issue 3, p487
- ISSN
1432-0428
- Publication type
Journal Article
- DOI
10.1007/s00125-010-1985-4